Articles tagged with Prostate Cancer
New research suggests that closely monitoring low-risk prostate cancer can be as effective as active treatment in reducing mortality rates and preserving sexual function. This approach allows men to live with the disease for ten years or more without treatment, while still being unlikely to die from it.
A phase 3 trial found that Lu-PSMA-617 significantly improved survival and progression-free survival of patients with metastatic castration-resistant prostate cancer. The treatment delivered beta radiation directly to tumour cells, keeping them alive for longer than standard care.
Researchers developed a miniature 3D bone-like tissue model to investigate the effects of anti-androgen therapies on prostate cancer bone tumours. The study found that traditional therapy had limited effect, with interactions between cancer cells and the bone microenvironment significantly impacting disease progress.
A new 'nomogram' helps predict which men with advanced metastatic prostate cancer will respond favorably to LuPSMA, a targeted therapy. The tool analyzes imaging and clinical data to stratify patients into high-risk or low-risk groups, enabling more personalized treatments.
A new AI-powered diagnostic tool can spot asymptomatic prostate cancer in routine CT scans, allowing for earlier diagnosis and improved treatment outcomes. The technology, developed at RMIT University, has been shown to perform better than human radiologists in detecting cancerous growths.
Men with high-risk prostate cancer benefit from multimodality care, which includes hormone therapy and radiation. The study found significant differences in deaths when guideline-concordant multimodality care was not delivered.
A new study found that Black men are 11% less likely to receive advanced prostate cancer therapies compared to non-Black men. Despite equal access to healthcare services, the disparity persists, with Black men also being more likely to die from the disease than non-Black patients.
Researchers identified a subset of localized prostate cancers that exhibit characteristics typical of 'hot' tumors, which may respond to immunotherapies. The study found that about a quarter of high-risk prostate cancers have these immunologic traits, suggesting a substantial number of patients may benefit from immunotherapy.
Researchers identify lineage plasticity as a deadly identity switch in castration-resistant prostate cancers, which can behave like small cell lung cancer. BET bromodomain inhibitors show promise in blocking this switch and overcoming treatment-emergent neuroendocrine prostate cancer.
A phase III clinical trial validates the effectiveness of 18F-DCFPyL in detecting and localizing recurrent prostate cancer, achieving high positive predictive values across various regions. The study's results support the use of PSMA-targeted radiotracers as the most sensitive and accurate agents for imaging prostate cancer.
Abdominal obesity is associated with an increased risk of developing aggressive prostate cancer, while general obesity does not show the same correlation. The research team recommends prioritizing studies on obesity exposure over a lifetime and further analysis of body fat distribution to better understand the risks.
Researchers identified glypican-1 protein that prevents cancer cells from spreading to bone, reducing aggressiveness. The study provides a potential new target for future treatments and supports previous findings suggesting the protein's role in preventing tumor growth.
A new treatment option has been developed to improve survival and disease control in men with advanced prostate cancer. The targeted radioligand therapy significantly extended survival and delayed progression, with a substantial effect given the high progression of disease despite previous treatments.
A nationwide Swedish study found that men with a family history of prostate cancer reach the screening risk threshold up to 12 years earlier than previously recommended, suggesting personalized screening approaches. The research suggests refining age guidelines for early screening based on individual family history factors.
Researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. Inhibiting the protein H6PD leads to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer.
Researchers found that areas with low environmental quality had stronger associations with late-stage prostate cancer diagnoses, particularly in Black men. The study suggests that addressing environmental factors such as land, water, and sociodemographic variables could improve treatment outcomes.
Researchers at UVA Cancer Center have unveiled new insights into how hormones known as androgens act on cells, which could lead to improved treatments for prostate, ovarian, and breast cancers. The study found that a complex signaling system regulates androgen receptor activity, using an enzyme called Parp7.
Researchers enrolled 50 Black and 50 white men with advanced prostate cancer to test hormone therapy abiraterone acetate plus prednisone. They found that Black men's PSA levels dropped further and more frequently, but disease progression and survival times were similar.
A new clinical trial is investigating the effectiveness of white button mushroom tablets in regulating immune systems and reducing prostate-specific antigen (PSA) levels. The study aims to recruit 132 male participants with recurrent prostate cancer, with results indicating potential benefits against prostate cancer.
A new study found a 36% decrease in prostate cancer diagnoses in Sweden during the first pandemic wave, with most pronounced declines among men aged 75 and over. The number of patients receiving curative treatment remained unaffected, suggesting that healthcare prioritized cancer care during the pandemic.
Researchers have developed a new urine test called ExoGrail, which shows how aggressive prostate cancer is and can reduce unnecessary biopsies. The test uses biomarkers to provide risk scores and identify patients who need invasive biopsies.
Researchers have discovered a new way to transform tissue surrounding prostate tumors to help the immune system fight cancer. The technique, called epigenetic reprogramming, could lead to improvements in immunotherapy treatments for prostate cancer.
Researchers at CU Cancer Center have discovered that tumor-suppressing genes MAP3K7 and CHD1 deletion increases androgen receptor signaling, making patients less responsive to anti-androgen therapy. This knowledge could lead to personalized treatment approaches for men with aggressive prostate cancer.
Tumor gene profiling decreases patient acceptance of active surveillance among men with clinically similar prostate cancers and low health literacy, a new study found. The study suggests that education on prostate cancer treatment options is needed for this population.
Research reveals associations between circulating tumor cell (CTC) mutations and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC). The study identified novel genetic alterations linked to response to AR inhibitors, including gains of ATM, NCOR2, and HSD17B4, which were associated with sensitivity to treatment.
Researchers at Duke University Medical Center identified a key reason hormone therapies fail and proposed a new treatment strategy directly targeting the cancer's fuel source, glutamine. By inhibiting glutamine utilization, tumor growth is successfully inhibited in studies using prostate cancer cell lines and animal models.
A mouse study suggests that white button mushroom extract can suppress androgen receptor activity in prostate cancer cells. The study also found that mice treated with the extract experienced reduced prostate tumor growth and decreased levels of PSA in their blood.
Researchers discovered microRNA-4287 inhibits prostate cancer's progression and metastasis, leading to increased cell cycle arrest. The study found miR-4287 specifically targets SLUG and CD44, suggesting a potential diagnostic and therapeutic tool against advanced prostate cancer.
A new study suggests that targeted screening for prostate cancer could prevent up to 16% of prostate cancer deaths and reduce overdiagnosis by 27%. The study, led by UCL researchers, recommends screening men with a high genetic risk profile using an MRI scan before biopsy.
A $1.06 million grant has been awarded to LSU Health New Orleans School of Medicine to explore a new treatment for Castrate Resistant Prostate Cancer (CPRC). The research focuses on the role of Prostate Derived ETS Transcription Factor (PDEF) in prostate cancer, with the goal of identifying novel targets for intervention.
The Cleveland African American Prostate Cancer Project aims to reduce health disparities by increasing prostate cancer screening among African American men. The project will develop and implement a comprehensive, sustainable program to screen for prostate cancer using barbershops as community hubs.
A genetic tool has been validated to estimate age of onset for aggressive prostate cancer in diverse ethnic/racial groups, with improved performance in men of African ancestry. The polygenic hazard score demonstrated excellent performance across European, Asian, and African genetic backgrounds.
Research from Baylor College of Medicine reveals that inhibiting MAPK4 can simultaneously activate and inhibit key cellular signaling pathways driving prostate cancer growth, suggesting a novel therapeutic strategy. This approach may provide a more effective treatment for advanced prostate cancer.
A new review highlights biological differences in prostate cancer development across ethnicities, identifying potential improvements for African American men. The study aims to reduce incidence and mortality rates by leveraging these differences.
A cross-disciplinary study combines canine olfaction with other detection methods to improve prostate cancer diagnosis. Dogs showed 71% sensitivity in detecting aggressive prostate cancer from urine samples, and an artificial neural network replicated their performance using spectroscopy data analysis.
Scientists at MIT develop system that detects chemical and microbial content of air samples with greater sensitivity than a dog's nose. The miniaturized detection system, coupled with machine-learning process, can identify distinctive characteristics of disease-bearing samples, matching success rates of dogs in detecting prostate cancer.
Researchers created a model to identify patients with high-risk prostate cancer who will benefit from the PSMA PET scan. The study found that patients with a Gleason score of 9 or 10 and high percent positive cores are most likely to benefit from the scan.
New research from Edith Cowan University found that exercise helps men with prostate cancer reduce symptoms of depression and anxiety, regardless of the type or intensity of exercise. The study suggests that supervised exercise is more beneficial than unsupervised exercise in reducing psychological distress.
A urine test has been found to be extremely accurate at detecting aggressive prostate cancer with few false negatives. The test avoids unnecessary biopsies for patients with slow-growing or no cancer, reducing costs and invasive procedures.
A retrospective study found that melatonin significantly improved the median overall survival of prostate cancer patients with poor prognosis, reducing mortality risk by more than twice. The antitumor effects of melatonin are fully realized in treating PCa patients with unfavorable tumor progression factors.
A new study discovered that Black men's tumors have a higher proportion of plasma cells, which correlates with improved cancer survival after surgery. This finding suggests that plasma cells may be key drivers of prostate cancer immune-responsiveness and could lead to personalized treatment options for men of all races.
The new risk score, developed by HKBU and CUHK researchers, uses urine spermine levels to estimate a patient's risk of developing prostate cancer. The test has been shown to accurately identify high-risk patients and help reduce unnecessary biopsies.
A new study published in the Journal of Nuclear Medicine found that combining radionuclide therapy with immunotherapy can slow prostate cancer progression and increase survival time. The treatment promotes prostate cancer immunogenicity, making tumors more receptive to immunotherapy.
A Phase III clinical trial has shown that Magnetic Resonance Imaging (MRI) with targeted biopsies can detect clinically significant prostate cancer more accurately and reduce the need for invasive procedures. The study found that MRI-TBx can help avoid unnecessary treatments and improve patient outcomes.
A new ultrasound technique called MRI-guided focused ultrasound ablation (MRgFUS) effectively treats intermediate-risk prostate cancer with minimal side effects. Treatment was successfully completed in all 44 men, with no major adverse events and 93% disease-free at the treatment site.
A team of researchers developed an AI analysis method to diagnose prostate cancer from urine within twenty minutes with almost 100% accuracy. The technique utilizes multiple cancer factors in urine to enhance diagnostic accuracy innovatively.
Scientists at Thomas Jefferson University discovered that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair mechanisms. The study found that CRY-1 is strongly associated with poor outcomes in late-stage prostate cancers.
A pooled data analysis suggests that drinking several cups of coffee daily may be associated with a lower risk of developing prostate cancer. The study found that each additional daily cup was linked to a relative risk reduction of nearly 1%, with the highest intake group showing a 9% lower risk compared to the lowest.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
A new study found that a Mediterranean-style diet may help slow the progression of prostate cancer in men who are not seeking immediate treatment. Men with localized prostate cancer who followed a more plant-based diet had a lower risk of cancer growth or advancement, regardless of their age, PSA levels, or tumor volume.
Australian researchers have discovered a new mechanism by which prostate cancer cells can adapt and evolve into more aggressive forms, making them resistant to treatment. The study highlights the importance of targeting microRNA-194 to slow down and inhibit the growth of prostate cancer models with neuroendocrine features.
A large-scale genetic analysis of over 200,000 men from diverse backgrounds identified 86 new risk factors for prostate cancer. The study found significant disparities in risk between racial and ethnic groups, with African American men inheriting twice the risk of European American counterparts.
Researchers found that blocking the androgen receptor reduces coronavirus infection in mice and cellular models. Anti-androgen treatments are already FDA-approved, opening up potential COVID-19 treatment options.
Researchers identified genomic heterogeneity and immune content scores that predict lethal outcomes in grade 4/5 prostate cancer patients. The study found that approximately 25% of these patients were more likely to benefit from targeted treatment strategies.
Researchers investigated delaying radical prostatectomy surgery for up to six months in patients with high-risk prostate cancer. The results indicate that delaying surgery may be associated with worse outcomes, highlighting the need for personalized treatment decisions.
The new PSMA PET imaging technique has been shown to detect significantly more prostate lesions than current standard-of-care techniques. This breakthrough could lead to better treatment outcomes and more precise care for men with prostate cancer.
Researchers found that providing genetic feedback to high-risk individuals improves their understanding and perceived value of the information. The study aims to improve healthcare by enabling personalized prevention plans and treatments for people with hereditary predispositions.
A study of 514 men undergoing active surveillance for early-stage prostate cancer found that those with negative biopsies had more favorable clinical characteristics and excellent long-term outcomes. Negative biopsies indicated low-volume disease with lower rates of disease progression, supporting continued active surveillance.
Researchers identified a genetic signature in localized prostate cancer that can predict metastasis and treatment response. The signature, called META-16, was highly effective at predicting time to metastasis and response to anti-androgen therapy.
A recent study found that men undergoing active surveillance for low-risk and intermediate-risk prostate cancer have very low rates of cancer spread and death from prostate cancer. The study analyzed 1,450 patients and identified three factors that affect the risk of metastases: Gleason grade, PSA velocity, and multiparametric MRI.